Autoimmunity in Rheumatoid Arthritis: Citrulline Immunity and Beyond

Advances in Immunology

Volumn 118, Issue , 2013, Pages 129-158

  Klareskog, Lars ^a   Lundberg, Karin ^a   Malmström, Vivianne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Arthritis; Autoimmune disease; Citrullination; Gene environment interactions; Tolerance

Indexed keywords

ALPHA ENOLASE; AUTOANTIGEN; COAL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; RHEUMATOID FACTOR; SILICON DIOXIDE;

ADAPTIVE IMMUNITY; ARTICLE; AUTOIMMUNITY; CELLULAR IMMUNITY; DISEASE MODEL; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENOTYPE; HEREDITY; HUMAN; IMMUNE RESPONSE; MEDICAL RESEARCH; MOLECULAR PATHOLOGY; NONHUMAN; PERSONALIZED MEDICINE; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROTEIN PROCESSING; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

EID: 84878050627     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407708-9.00003-0     Document Type: Chapter

References (142)

1. Ahlqvist E., Hultqvist M., Holmdahl R. The value of animal models in predicting genetic susceptibility to complex diseases such as rheumatoid arthritis. Arthritis Research & Therapy 2009, 11(3):226.
2. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism 2010, 62(9):2569-2581.
3. Amara K., Steen J., Murray F., Morbach H., Fernandez-Rodriguez B.M., Snir O. Monoclonal IgG antibody generation from joint-derived B cells of Ra patients-Strong bias towards autoantigen recognition. Journal of Experimental Medicine 2013, 210(3):445-455.
4. Andrade F., Darrah E., Gucek M., Cole R.N., Rosen A., Zhu X. Autocitrullination of human peptidyl arginine deiminase type 4 regulates protein citrullination during cell activation. Arthritis and Rheumatism 2010, 62(6):1630-1640.
5. Arechiga A.F., Habib T., He Y., Zhang X., Zhang Z.Y., Funk A., et al. Cutting edge: The PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. Journal of Immunology 2009, 182(6):3343-3347.
6. Arend W.P., Firestein G.S. Pre-rheumatoid arthritis: Predisposition and transition to clinical synovitis. Nature Reviews. Rheumatology 2012, 8(10):573-586.
7. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988, 31(3):315-324.
8. Askling J., Fored C.M., Geborek P., Jacobsson L.T., van Vollenhoven R., Feltelius N. Swedish registers to examine drug safety and clinical issues in RA. Annals of the Rheumatic Diseases 2006, 65(6):707-712.
9. Aslam A., Chapel H., Ogg G. Direct ex-vivo evaluation of pneumococcal specific T-cells in healthy adults. PLoS One 2011, 6(10):e25367.
10. Auger I., Sebbag M., Vincent C., Balandraud N., Guis S., Nogueira L., et al. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis and Rheumatism 2005, 52(11):3424-3432.
11. Bagaitkar J., Daep C.A., Patel C.K., Renaud D.E., Demuth D.R., Scott D.A. Tobacco smoke augments Porphyromonas gingivalis-Streptococcus gordonii biofilm formation. PLoS One 2011, 6(11):e27386. 10.1371/journal.pone.0027386.
12. Barnett M.L., Kremer J.M., St Clair E.W., Clegg D.O., Furst D., Weisman M., et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis and Rheumatism 1998, 41(2):290-297. Erratum in: Arthritis Rheum 1998 May;41(5):938.
13. Barton A., Thomson W., Ke X., Eyre S., Hinks A., Bowes J., et al. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Human Molecular Genetics 2008, 17(15):2274-2279.
14. Bax M., van Heemst J., Huizinga T.W., Toes R.E. Genetics of rheumatoid arthritis: What have we learned?. Immunogenetics 2011, 63(8):459-466.
15. Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J., Chokkalingam A.P., Alexander H.C., et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. American Journal of Human Genetics 2004, 75(2):330-337.
16. Bengtsson C., Berglund A., Serra M.L., Nise L., Nordmark B., Klareskog L., et al. Non-participation in EIRA: A population-based case-control study of rheumatoid arthritis. Scandinavian Journal of Rheumatology 2010, 39(4):344-346.
17. Bjorkman P.J., Saper M.A., Samraoui B., Bennett W.S., Strominger J.L., Wiley D.C. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987, 329(6139):512-518.
18. Brink M., Hansson M., Mathsson L., Jakobsson P.J., Holmdahl R., Hallmans G., et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis and Rheumatism 2013, Jan 10. [Epub ahead of print].
19. Burkhardt H., Hüffmeier U., Spriewald B., Böhm B., Rau R., Kallert S., et al. Association between protein tyrosine phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope and humoral autoimmunity to an immunodominant epitope of cartilage-specific type II collagen in early rheumatoid arthritis. Arthritis and Rheumatism 2006, 54(1):82-89.
20. Cantaert T., Brouard S., Thurlings R.M., Pallier A., Salinas G.F., Braud C., et al. Alterations of the synovial T cell repertoire in anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis and Rheumatism 2009, 60(7):1944-1956.
21. Caplan A. Rheumatoid disease and pneumoconiosis (Caplan's syndrome). Proceedings of the Royal Society of Medicine 1959, 52:1111-1113.
22. Carlsén S., Hansson A.S., Olsson H., Heinegård D., Holmdahl R. Cartilage oligomeric matrix protein (COMP)-induced arthritis in rats. Clinical and Experimental Immunology 1998, 114(3):477-484.
23. Carlsen S., Lu S., Holmdahl R. Arthritis induced with minor cartilage proteins. Methods in Molecular Medicine 2007, 136:225-242.
24. Chapuy-Regaud S., Sebbag M., Baeten D., Clavel C., Foulquier C., De Keyser F., et al. Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides. Journal of Immunology 2005, 174(8):5057-5064.
25. Chibnik L.B., Mandl L.A., Costenbader K.H., Schur P.H., Karlson E.W. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. Journal of Rheumatology 2009, 36(4):706-711.
26. Chun-Lai T., Padyukov L., Dhaliwal J.S., Lundström E., Yahya A., Muhamad N.A., et al. Shared epitope alleles remain a risk factor for anti-citrullinated proteins antibody (ACPA)-positive rheumatoid arthritis in three Asian ethnic groups. PLoS One 2011, 6(6):e21069.
27. Criswell L.A., Gregersen P.K. Current understanding of the genetic aetiology of rheumatoid arthritis and likely future developments. Rheumatology (Oxford, England) 2005, 44(Suppl. 4):iv9-iv13.
28. de Rooy D.P., van der Linden M.P., Knevel R., Huizinga T.W., van der Helm-van Mil A.H. Predicting arthritis outcomes-What can be learned from the Leiden Early Arthritis Clinic?. Rheumatology (Oxford, England) 2011, 50(1):93-100.
29. Dinarello C.A., Simon A., van der Meer J.W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews. Drug Discovery 2012, 11(8):633-652.
30. Ding B., Padyukov L., Lundström E., Seielstad M., Plenge R.M., Oksenberg J.R., et al. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis and Rheumatism 2009, 60(1):30-38. Erratum in: Arthritis Rheum. 2009 Apr;60(4):1200.
31. Dostert C., Pétrilli V., Van Bruggen R., Steele C., Mossman B.T., Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320(5876):674-677.
32. Dzhambazov B., Nandakumar K.S., Kihlberg J., Fugger L., Holmdahl R., Vestberg M. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. Journal of Immunology 2006, 176(3):1525-1533.
33. El-Gabalawy H.S., Robinson D.B., Smolik I., Hart D., Elias B., Wong K., et al. Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis and Rheumatism 2012, 64(6):1720-1729.
34. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344(8930):1105-1110.
35. Eyre S., Bowes J., Diogo D., Lee A., Barton A., Martin P., et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nature Genetics 2012, 44(12):1336-1340.
36. Girbal-Neuhauser E., Durieux J.J., Arnaud M., Dalbon P., Sebbag M., Vincent C., et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. Journal of Immunology 1999, 162(1):585-594.
37. Goldberg B., Bona C. Dimeric MHC-peptides inserted into an immunoglobulin scaffold as new immunotherapeutic agents. Journal of Cellular and Molecular Medicine 2011, 15(9):1822-1832.
38. Gregersen P.K., Silver J., Winchester R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis and Rheumatism 1987, 30(11):1205-1213. Review.
39. Hansson M., Mathsson L., Schlederer T., Israelsson L., Matsson P., Nogueira L., et al. Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides. Arthritis Research & Therapy 2012, 14(5):R201.
40. Harre U., Georgess D., Bang H., Bozec A., Axmann R., Ossipova E., et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. The Journal of Clinical Investigation 2012, 122(5):1791-1802.
41. Harris M.L., Darrah E., Lam G.K., Bartlett S.J., Giles J.T., Grant A.V., et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis and Rheumatism 2008, 58(7):1958-1967.
42. Harry R.A., Anderson A.E., Isaacs J.D., Hilkens C.M. Generation and characterization of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Annals of the Rheumatic Diseases 2010, 69(11):2042-2050.
43. Hart J.E., Källberg H., Laden F., Bellander T., Costenbader K.H., Holmqvist M., et al. Ambient air pollution exposures and risk of rheumatoid arthritis: Results from the Swedish EIRA case-control study. Annals of the Rheumatic Diseases 2012, Jul 24 [Epub ahead of print].
44. Hart J.E., Laden F., Puett R.C., Costenbader K.H., Karlson E.W. Exposure to traffic pollution and increased risk of rheumatoid arthritis. Environmental Health Perspectives 2009, 117(7):1065-1069.
45. Hill J.A., Bell D.A., Brintnell W., Yue D., Wehrli B., Jevnikar A.M., et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. The Journal of Experimental Medicine 2008, 205(4):967-979.
46. *0401 MHC class II molecule. Journal of Immunology 2003, 171(2):538-541.
47. Hoffmann M.H., Tuncel J., Skriner K., Tohidast-Akrad M., Türk B., Pinol-Roma S., et al. The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis. Journal of Immunology 2007, 179(11):7568-7576.
48. Holmdahl R. Dissection of the genetic complexity of arthritis using animal models. Immunology Letters 2006, 103(2):86-91.
49. Horai R., Saijo S., Tanioka H., Nakae S., Sudo K., Okahara A., et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. The Journal of Experimental Medicine 2000, 191(2):313-320.
50. Hughes-Austin J.M., Deane K.D., Derber L.A., Kolfenbach J.R., Zerbe G.O., Sokolove J., et al. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA). Annals of the Rheumatic Diseases 2012.
51. Huizinga T.W., Amos C.I., van der Helm-van Mil A.H., Chen W., van Gaalen F.A., Jawaheer D., et al. Refining the complex rheumatoid arthritis. Phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis and Rheumatism 2005, 52(11):3433-3438.
52. Ioan-Facsinay A., el-Bannoudi H., Scherer H.U., van der Woude D., Ménard H.A., Lora M., et al. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Annals of the Rheumatic Diseases 2011, 70(1):188-193.
53. James E.A., Moustakas A.K., Bui J., Papadopoulos G.K., Bondinas G., Buckner J.H., Kwok W.W. HLA-DR 1001 presents "altered-self" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis and Rheumatism 2010, 62(10):2909-2918.
54. Janossy G., Panayi G., Duke O., Bofill M., Poulter L.W., Goldstein G. Rheumatoid arthritis: A disease of T-lymphocyte/macrophage immunoregulation. Lancet 1981, 2(8251):839-842.
55. Kallberg H., Ding B., Padyukov L., Bengtsson C., Rönnelid J., Klareskog L., et al. Smoking is a major preventable risk factor for rheumatoid arthritis: Estimations of risks after various exposures to cigarette smoke. Annals of the Rheumatic Diseases 2010, 70(3):508-511.
56. Källberg H., Padyukov L., Plenge R.M., Ronnelid J., Gregersen P.K., van der Helm-van Mil A.H., et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. American Journal of Human Genetics 2007, 80(5):867-875.
57. Karlson E.W., Chang S.C., Cui J., Chibnik L.B., Fraser P.A., De Vivo I., et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Annals of the Rheumatic Diseases 2010, 69(1):54-60.
58. Kassiotis G., Bauer J., Akassoglou K., Lassmann H., Kollias G., Probert L. A tumor necrosis factor-induced model of human primary demyelinating diseases develops in immunodeficient mice. European Journal of Immunology 1999, 29(3):912-917.
59. Kinloch A.J., Alzabin S., Brintnell W., Wilson E., Barra L., Wegner N., et al. Immunization with Porphyromonas gingivalis enolase induces autoimmunity to mammalian α-enolase and arthritis in DR4-IE-transgenic mice. Arthritis and Rheumatism 2011, 63(12):3818-3823.
60. Klareskog L., Forsum U., Malmnäs Tjernlund U.K., Kabelitz D., Wigren A. Appearance of anti-HLA-DR-reactive cells in normal and rheumatoid synovial tissue. Scandinavian Journal of Immunology 1981, 14(2):183-192.
61. Klareskog L., Malmström V., Lundberg K., Padyukov L., Alfredsson L. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Seminars in Immunology 2011, 23(2):92-98.
62. Klareskog L., Rönnelid J., Lundberg K., Padyukov L., Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annual Review of Immunology 2008, 26:651-675.
63. Klareskog L., Stolt P., Lundberg K., Källberg H., Bengtsson C., Grunewald J., et al. A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis and Rheumatism 2006, 54(1):38-46.
64. Kleinau S., Erlandsson H., Holmdahl R., Klareskog L. Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement. Journal of Autoimmunity 1991, 4(6):871-880.
65. Korn T., Mitsdoerffer M., Croxford A.L., Awasthi A., Dardalhon V.A., Galileos G., et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(47):18460-18465.
66. Kuhn K.A., Kulik L., Tomooka B., Braschler K.J., Arend W.P., Robinson W.H., et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. The Journal of Clinical Investigation 2006, 116(4):961-973.
67. Kurki P., Aho K., Palosuo T., Heliövaara M. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis and Rheumatism 1992, 35(8):914-917.
68. Lee H.S., Lee A.T., Criswell L.A., Seldin M.F., Amos C.I., Carulli J.P., et al. Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus. Molecular Medicine 2008, 14(5-6):293-300.
69. Long S.A., Walker M.R., Rieck M., James E., Kwok W.W., Sanda S., et al. Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects. European Journal of Immunology 2009, 39(2):612-620.
70. Lu M.C., Lai N.S., Yu H.C., Huang H.B., Hsieh S.C., Yu C.L. Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production. Arthritis and Rheumatism 2010, 62(5):1213-1223.
71. Ludvigsson J., Krisky D., Casas R., Battelino T., Castaño L., Greening J., et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. The New England Journal of Medicine 2012, 366(5):433-442.
72. Lundberg K., Bengtsson C., Kharlamova N., Reed E., Jiang X., Kallberg H., et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Annals of the Rheumatic Diseases 2012, Sep 8. [Epub ahead of print].
73. Lundberg K., Kinloch A., Fisher B.A., Wegner N., Wait R., Charles P., et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis and Rheumatism 2008, 58(10):3009-3019.
74. Lundberg K., Nijenhuis S., Vossenaar E.R., Palmblad K., van Venrooij W.J., Klareskog L., et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Research & Therapy 2005, 7(3):R458-R467.
75. Lundberg K., Wegner N., Yucel-Lindberg T., Venables P.J. Periodontitis in RA-The citrullinated enolase connection. Nature Reviews. Rheumatology 2010, 6(12):727-730.
76. Lutterotti A., Sospedra M., Martin R. Antigen-specific therapies in MS-Current concepts and novel approaches. Journal of the Neurological Sciences 2008, 274(1-2):18-22.
77. Mahdi H., Fisher B.A., Källberg H., Plant D., Malmström V., Rönnelid J., et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nature Genetics 2009, 41(12):1319-1324.
78. Makrygiannakis D., Hermansson M., Ulfgren A.K., Nicholas A.P., Zendman A.J., Eklund A., et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Annals of the Rheumatic Diseases 2008, 67(10):1488-1492.
79. Malmström V., Pieper J., Rieck M., Sandin C., James E., Klareskog L., et al. HLA class II tetramer detection of a-enolase specific T cells in rheumatoid arthritis 2012, 474-475. Glasgow, Scotland, Sep 5-8, 2012, Immunology, Vol. 137 (SI, Suppl. 1).
80. Matsumoto I., Lee D.M., Goldbach-Mansky R., Sumida T., Hitchon C.A., Schur P.H., et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis and Rheumatism 2003, 48(4):944-954.
81. Matsumoto I., Staub A., Benoist C., Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999, 286(5445):1732-1735.
82. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine 2011, 365(23):2205-2219.
83. Menard L., Saadoun D., Isnardi I., Ng Y.S., Meyers G., Massad C., et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. The Journal of Clinical Investigation 2011, 121(9):3635-3644.
84. Mikuls T.R., Thiele G.M., Deane K.D., Payne J.B., O'Dell J.R., Yu F., et al. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis and Rheumatism 2012, 64(11):3522-3530.
85. Mullazehi M., Mathsson L., Lampa J., Rönnelid J. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset. Annals of the Rheumatic Diseases 2006, 66(4):537-541.
86. Mydel P., Wang Z., Brisslert M., Hellvard A., Dahlberg L.E., Hazen S.L., et al. Carbamylation-dependent activation of T cells: A novel mechanism in the pathogenesis of autoimmune arthritis. Journal of Immunology 2010, 184(12):6882-6890.
87. Nandakumar K.S., Bajtner E., Hill L., Böhm B., Rowley M.J., Burkhardt H., et al. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis and Rheumatism 2008, 58(1):184-196.
88. Nielen M.M., van Schaardenburg D., Reesink H.W., van de Stadt R.J., van der Horst-Bruinsma I.E., de Koning M.H., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis and Rheumatism 2004, 50(2):380-386.
89. Ohsugi Y., Kishimoto T. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 2008, 8(5):669-681.
90. Olofsson P., Holmdahl R. Pristane-induced arthritis in the rat. Methods in Molecular Medicine 2007, 136:255-268.
91. Padyukov L., Silva C., Stolt P., Alfredsson L., Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis and Rheumatism 2004, 50(10):3085-3092.
92. Panayi G.S., Corrigall V.M. BiP regulates autoimmune inflammation and tissue damage. Autoimmunity Reviews 2006, 5(2):140-142.
93. Pedersen M., Jacobsen S., Garred P., Madsen H.O., Klarlund M., Svejgaard A., et al. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: A nationwide case-control study in Denmark. Arthritis and Rheumatism 2007, 56(5):1446-1453.
94. Plenge R.M., Padyukov L., Remmers E.F., Purcell S., Lee A.T., Karlson E.W., et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: Association of susceptibility with PTPN22, CTLA4, and PADI4. American Journal of Human Genetics 2005, 77(6):1044-1060.
95. Plenge R.M., Seielstad M., Padyukov L., Lee A.T., Remmers E.F., Ding B., et al. TRAF1-C5 as a risk locus for rheumatoid arthritis-A genomewide study. The New England Journal of Medicine 2007, 357(12):1199-1209.
96. Qiao S.W., Iversen R., Ráki M., Sollid L.M. The adaptive immune response in celiac disease. Seminars in Immunopathology 2012, 34(4):523-540.
97. Ráki M., Fallang L.E., Brottveit M., Bergseng E., Quarsten H., Lundin K.E., et al. Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of celiac disease patients. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(8):2831-2836.
98. Rantapää-Dahlqvist S., de Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis and Rheumatism 2003, 48(10):2741-2749.
99. Raychaudhuri S. Recent advances in the genetics of rheumatoid arthritis. Current Opinion in Rheumatology 2010, 22(2):109-118.
100. Raychaudhuri S., Sandor C., Stahl E.A., Freudenberg J., Lee H.S., Jia X., et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nature Genetics 2012, 44(3):291-296.
101. Raza K., Mullazehi M., Salmon M., Buckley C.D., Rönnelid J. Anti-collagen type II antibodies in patients with very early synovitis. Annals of the Rheumatic Diseases 2008, 67(9):1354-1355.
102. Reparon-Schuijt C.C., van Esch W.J., van Kooten C., Schellekens G.A., de Jong B.A., van Venrooij W.J., et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis and Rheumatism 2001, 44(1):41-47.
103. Rohrbach A.S., Slade D.J., Thompson P.R., Mowen K.A. Activation of PAD4 in NET formation. Frontiers in Immunology 2012, 3:360. 10.3389/fimmu.2012.00360.
104. Sánchez-Guerrero J., Colditz G.A., Karlson E.W., Hunter D.J., Speizer F.E., Liang M.H. Silicone breast implants and the risk of connective-tissue diseases and symptoms. The New England Journal of Medicine 1995, 332(25):1666-1670.
105. Schellekens G.A., de Jong B.A., van den Hoogen F.H., van de Putte L.B., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. The Journal of Clinical Investigation 1998, 101(1):273-281.
106. Schellekens G.A., Visser H., de Jong B.A., van den Hoogen F.H., Hazes J.M., Breedveld F.C., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and Rheumatism 2000, 43(1):155-163.
107. Scher J.U., Ubeda C., Equinda M., Khanin R., Buischi Y., Viale A., et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis and Rheumatism 2012, 64(10):3083-3094.
108. Shi J., Knevel R., Suwannalai P., van der Linden M.P., Janssen G.M., van Veelen P.A., et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(42):17372-17377.
109. Shoda H., Fujio K., Shibuya M., Okamura T., Sumitomo S., Okamoto A., et al. Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Research & Therapy 2011, 13(6):R191.
110. Skriner K., Sommergruber W.H., Tremmel V., Fischer I., Barta A., Smolen J.S., et al. Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. The Journal of Clinical Investigation 1997, 100(1):127-135.
111. *0401-positive humanized mice and rheumatoid arthritis patients. Arthritis and Rheumatism 2011, 63(10):2873-2883.
112. Snir O., Widhe M., Hermansson M., von Spee C., Lindberg J., Hensen S., et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis and Rheumatism 2010, 62(1):44-52.
113. Snir O., Widhe M., von Spee C., Lindberg J., Padyukov L., Lundberg K., et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: Association with HLA-DRB1 alleles. Annals of the Rheumatic Diseases 2009, 68(5):736-743.
114. Sokolove J., Lindstrom T.M., Robinson W.H. Development and deployment of antigen arrays for investigation of B-cell fine specificity in autoimmune disease. Frontiers in Bioscience (Elite Edition) 2012, 4:320-330.
115. Sokolove J., Zhao X., Chandra P.E., Robinson W.H. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor. Arthritis and Rheumatism 2011, 63(1):53-62.
116. Stahl E.A., Raychaudhuri S., Remmers E.F., Xie G., Eyre S., Thomson B.P., et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genetics 2010, 42(6):508-514.
117. Stastny P. Mixed lymphocyte cultures in rheumatoid arthritis. The Journal of Clinical Investigation 1976, 57(5):1148-1157.
118. Steinman R.M. Decisions about dendritic cells: Past, present, and future. Annual Review of Immunology 2011, 30:1-22.
119. Stolt P., Bengtsson C., Nordmark B., Lindblad S., Lundberg I., Klareskog L., et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: Results from a population based case-control study, using incident cases. Annals of the Rheumatic Diseases 2003, 62(9):835-841.
120. Stolt P., Yahya A., Bengtsson C., Källberg H., Rönnelid J., Lundberg I., et al. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis. Annals of the Rheumatic Diseases 2010, 69(6):1072-1076.
121. Sun J.B., Czerkinsky C., Holmgren J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scandinavian Journal of Immunology 2010, 71(1):1-11. 10.1111/j.1365-3083.2009.02321.x.
122. Suwannalai P., van de Stadt L.A., Radner H., Steiner G., El-Gabalawy H.S., Zijde C.M., et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis and Rheumatism 2012, 64(5):1323-1328.
123. Symmons D.P., Silman A.J. Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register. Arthritis Research & Therapy 2006, 8(4):214.
124. Thomson W., Barton A., Ke X., Eyre S., Hinks A., Bowes J., et al. Rheumatoid arthritis association at 6q23. Nature Genetics 2007, 39(12):1431-1433. Epub 2007 Nov 4.
125. Tiller T., Meffre E., Yurasov S., Tsuiji M., Nussenzweig M.C., Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. Journal of Immunological Methods 2008, 329(1-2):112-124. Epub 2007 Oct 31. Erratum in: Journal of Immunological Methods, 334(1-2), 142, 2008.
126. Trouw L.A., Huizinga T.W., Toes R.E. Autoimmunity in rheumatoid arthritis: Different antigens-Common principles. Annals of the Rheumatic Diseases 2012, [Epub ahead of print].
127. Uysal H., Bockermann R., Nandakumar K.S., Sehnert B., Bajtner E., Engström A., Serre G., et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. The Journal of Experimental Medicine 2009, 206(2):449-462.
128. van Beers J.J., Schwarte C.M., Stammen-Vogelzangs J., Oosterink E., Božič B., Pruijn G.J. The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and β-actin. Arthritis and Rheumatism 2013, 65(1):69-80.
129. van de Stadt L.A., de Koning M.H., van de Stadt R.J., Wolbink G., Dijkmans B.A., Hamann D., et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis and Rheumatism 2011, 63(11):3226-3233.
130. van der Linden M.P., Knevel R., Huizinga T.W., van der Helm-van Mil A.H. Classification of rheumatoid arthritis: Comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis and Rheumatism 2011, 63(1):37-42.
131. van der Woude D., Alemayehu W.G., Verduijn W., de Vries R.R., Houwing-Duistermaat J.J., Huizinga T.W., et al. Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nature Genetics 2010, 42(10):814-816.
132. van Venrooij W.J., van Beers J.J., Pruijn G.J. Anti-CCP antibodies: The past, the present and the future. Nature Reviews. Rheumatology 2011, 7(7):391-398.
133. von Boehmer H., Waldmann H. Immunological tolerance. Frontiers in Immunology 2010, 1:102.
134. Waaler E. On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939. APMIS 2007, 15(5):422-438. discussion 439.
135. Wambre E., DeLong J.H., James E.A., LaFond R.E., Robinson D., Kwok W.W. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. The Journal of Allergy and Clinical Immunology 2011, 129(2):544-551. 551.e1-7.
136. Wambre E., James E.A., Kwok W.W. Characterization of CD4+ T cell subsets in allergy. Current Opinion in Immunology 2012, 24(6):700-706.
137. Wegner N., Lundberg K., Kinloch A., Fisher B., Malmström V., Feldmann M., et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunological Reviews 2010, 233(1):34-54.
138. Wegner N., Wait R., Sroka A., Eick S., Nguyen K.A., Lundberg K., et al. Peptidylarginine deiminase from Pophyromonas gingivalis citrullinates human fibrinogen and α-enolase: Implications for autoimmunity in rheumatoid arthritis. Arthritis and Rheumatism 2010, 62(9):2662-2672.
139. Willemze A., Trouw L.A., Toes R.E., Huizinga T.W. The influence of ACPA status and characteristics on the course of RA. Nature Reviews. Rheumatology 2012, 8(3):144-152.
140. Willemze A., van der Woude D., Ghidey W., Levarht E.W., Stoeken-Rijsbergen G., Verduyn W., et al. The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Arthritis and Rheumatism 2011, 63(7):1823-1832.
141. Wooley P.H., Luthra H.S., Stuart J.M., David C.S. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. The Journal of Experimental Medicine 1981, 154(3):688-700.
142. Zielinski C.E., Mele F., Aschenbrenner D., Jarrossay D., Ronchi F., Gattorno M., et al. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 2012, 484(7395):514-518.